Combining biomarkers for prognostic modelling of Parkinson’s disease

Vijiaratnam, N. et al. (2022) Combining biomarkers for prognostic modelling of Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 93(7), pp. 707-715. (doi: 10.1136/jnnp-2021-328365) (PMID:35577512) (PMCID:PMC9279845)

[img] Text
271290.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Background: Patients with Parkinson’s disease (PD) have variable rates of progression. More accurate prediction of progression could improve selection for clinical trials. Although some variance in clinical progression can be predicted by age at onset and phenotype, we hypothesise that this can be further improved by blood biomarkers. Objective: To determine if blood biomarkers (serum neurofilament light (NfL) and genetic status (glucocerebrosidase, GBA and apolipoprotein E (APOE))) are useful in addition to clinical measures for prognostic modelling in PD. Methods: We evaluated the relationship between serum NfL and baseline and longitudinal clinical measures as well as patients’ genetic (GBA and APOE) status. We classified patients as having a favourable or an unfavourable outcome based on a previously validated model, and explored how blood biomarkers compared with clinical variables in distinguishing prognostic phenotypes . Results: 291 patients were assessed in this study. Baseline serum NfL was associated with baseline cognitive status. Nfl predicted a shorter time to dementia, postural instability and death (dementia—HR 2.64; postural instability—HR 1.32; mortality—HR 1.89) whereas APOEe4 status was associated with progression to dementia (dementia—HR 3.12, 95% CI 1.63 to 6.00). NfL levels and genetic variables predicted unfavourable progression to a similar extent as clinical predictors. The combination of clinical, NfL and genetic data produced a stronger prediction of unfavourable outcomes compared with age and gender (area under the curve: 0.74-age/gender vs 0.84-ALL p=0.0103). Conclusions: Clinical trials of disease-modifying therapies might usefully stratify patients using clinical, genetic and NfL status at the time of recruitment.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Grosset, Professor Donald and Grosset, Dr Katherine
Authors: Vijiaratnam, N., Lawton, M., Heslegrave, A. J., Guo, T., Tan, M., Jabbari, E., Real, R., Woodside, J., Grosset, K., Chelban, V., Athauda, D., Girges, C., Barker, R. A., Hardy, J., Wood, N., Houlden, H., Williams, N., Ben-Shlomo, Y., Zetterberg, H., Grosset, D. G., Foltynie, T., and Morris, H. R.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience
Journal Name:Journal of Neurology, Neurosurgery and Psychiatry
Publisher:BMJ Publishing Group
ISSN:0022-3050
ISSN (Online):1468-330X
Published Online:16 May 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Journal of Neurology, Neurosurgery and Psychiatry 93(7): 707-715
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record